Publications found:
105,749
Sort by:
ARQULE - Positive Data in HCC is an Add-On!
US$ 140.00
Positive PhII data of Tivantinib (formerly ARQ-197, c-MET inhibitor) in ... raises expectations and the efficacy bar for Tivantinib. We remain positive on an approval of Tivantinib in its lead indication – NSCLC ... read our report released on 19th January, 2012 on ArQule titled “Positive Data in HCC is an Add-On!”
January 2012
3 pages
REGENERON – Eylea Sales Add a Sparkle to The Eye!
US$ 120.00
... and Avastin (off-label), Regeneron (REGN) overwhelmed all concerns of a “weak launch” of Eylea (VEGF Trap-Eye, L, ... Bill” model! Uptake at this pace should entitle Eylea to capture…. Moreover, CEO’s optimism around REGN’s ... released on 11th January, 2012 on Regeneron titled “Eylea Sales Add a Sparkle to The Eye!”
January 2012
6 pages
REGENERON - Eylea’s Litigation Settlement = Good Start to 2012!
US$ 90.00
Regeneron (REGN) settled its patent litigation with Genentech (Roche) over Eylea (VEGF Trap-Eye, L, partnered ... payments to Roche -$60m when cumulative US sales of Eylea reach $400m + will pay royalties of 4.75% on ... 6th January, 2012 on Regeneron titled “Eylea’s Litigation Settlement = Good Start to 2012!”
January 2012
6 pages
AVEO Pharma - PhIII, TIVO-1 Data and Reaction - No Surprise!
US$ 90.00
Data from TIVO-1, PhIII study (head-to-head study with ONXX’s Nexavar) of Tivozanib (formerly AV- ... details, please read our report released on 4th January, 2012 on AVEO pharma titled “PhIII, TIVO-1 Data and Reaction - No Surprise!”
January 2012
3 pages
US Telecom Industry Assessment & Forecasts 2011 - 2020
US$ 2,500.00
The US Telecom industry is a complex business with numerous segments, which has undergone strong growth over the past ten years. Recent history ... through the year 2020 to reach almost $1.2 trillion in revenue. As penetration of a number of Telecom categories reaches over 90%, growth over the next ten years ...
January 2012
45 pages
Charter Schools: Market Research Report
US$ 2,950.00
... collection of statistical anecdotes, market briefs, and concise summaries of research findings. Illustrated with 31 fact-rich market data tables, the report offers an aerial view of the Charter Schools industry in the US, identifies major short to medium term market ...
December 2011
128 pages
US Biotech Market Analysis
US$ 1,000.00
The US represents the world’s largest biotechnology market, leading with its innovation, extensive R&D, and regular company developments in various spheres of the biotechnology sector. On the back...
December 2011
65 pages
Affluent Consumer Market in the U.S., 6th Edition
US$ 3,850.00
This completely new edition of Packaged Facts The Affluent Consumer Market in the U.S. finds an affluent consumer population that is considerably more upbeat than in 2009 when the last edition of th...
December 2011
180 pages
US Healthcare Market Outlook 2013
US$ 1,000.00
The US represents the world’s largest healthcare market, with a high annual healthcare spending. The growth in healthcare spending is mainly driven by high administrative costs, and expensive hospital...
December 2011
80 pages
US Cement Industry Analysis
US$ 1,000.00
US being the world's largest economy and one of the most dynamic construction markets provided a substantial platform to its cement industry for expansion over the last two decades. However, last few...
December 2011
70 pages
Outlook 2012 - Rising Stars - Innovators Deliver but Rewards Not Guranteed!
US$ 2,000.00
... continue to flow from the backyards of small research focused companies (Rising stars, RS) but commercial success of launched products is not assured despite patents ... Micromet (MITI) are our Top Picks for FY2012 in the Rising Stars Sector. Key drugs of ANTH and MITI target high unmet ...
December 2011
52 pages
Analyzing Base Metals in the United States
US$ 350.00
... in the US. Aruvians Rsearch analyzes the US base metals market in its research report Analyzing Base Metals in the United States. The report is a complete coverage of the base metals industry in the United States. In this in-depth ...
December 2011
60 pages
Outlook 2012 - Mature Biotech - Investing in Growth and Value buys!
US$ 2,000.00
... ’ in 2011! We expect a similar trend of acquisitions and in-licensing of better molecules in 2012 and beyond, as MB companies have robust cash flow to further leverage ... Gilead (GILD) are our Top Picks for FY2012 in the Mature Biotech Sector. BIIB’s focus and leadership in the MS market and positive ...
December 2011
46 pages
Audiobooks in America: Trends and Market Details 2012
US$ 1,295.00
Audiobooks in America: Trends and Market Details 2012 compiles the most recent data from Experian Simmons and augments it with Simba’s proprietary intelligence to present the comprehensive review of...
December 2011
200 pages
Yoghurt and Sour Milk Drinks in the US
US$ 990.00
... consumers’ desire for a convenient, nutritious and tasty... Euromonitor International's Yoghurt and Sour Milk Drinks in USA report offers a comprehensive guide to the size and ... , Condensed/Evaporated Milk, Cream, Flavoured Milk Drinks, Flavoured Powder Milk Drinks, Fromage Frais and Quark, Milk, Powder Milk, Processed Cheese, Sour Milk Drinks, Soy Beverages, Unprocessed Cheese, Yoghurt. Data ...
November 2011
83 pages
Onyx Pharma, Market Perform - M&A Rumors Fuel Investors Interest and Stock Movement
US$ 90.00
Recent news about “possible acquisition of Onyx pharma” is not a surprise in light of the upcoming ... over Regorafenib (BAY73-4506, PhIII) with Bayer. Onyx product pipeline focuses only in oncology. We have ... released on 30th November, 2011 on Onyx pharma titled “M&A Rumors Fuel Investors Interest and Stock ...
November 2011
6 pages
AMGN - Old is Gold = Value Buy!
US$ 140.00
... philosophy to pursue “innovation” in a balanced way should keep shareholders interested in AMGN for long term. PhIII data from study ‘147 published ... more detail, please read our report released on 25th November on AMGN titled “AMGN - Old is Gold = Value Buy!”
November 2011
4 pages
Vertex – “Testing Time Ahead for INCIVEK - After 2013!”
US$ 140.00
... in 2014, would result in declining sales for INCIVEK/IFN combination. Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients ... read our report released on 25th November, 2011 on VRTX titled “Testing Time Ahead for INCIVEK - After 2013!”
November 2011
10 pages
US Glucose Monitoring Market Analysis
US$ 1,000.00
The US has a dominant share in the global diabetes market with 90-95% of the diabetic patients in the country suffering from type-II diabetes. Factors like, high prevalence of diabetes, rising aging p...
November 2011
55 pages
Latino Foodservice Trends in the U.S.
US$ 3,995.00
... Hispanic guest traffic volume and growth Analysis of “hot” ethnic cuisine trends; Mexican menu items; Caribbean, Mexican, South American menu item ... sales) are growing Hispanic share This report covers Latino foodservice trends in the United States. Scope of analysis is limited largely to the full- ...
November 2011
132 pages
U.S. and European Markets for Orthopedic Trauma Devices by Anatomy 2011
US$ 11,495.00
... U.S. market, the largest in the world, comprised 76.2% of the combined market. The U.S. and European trauma markets comprise: external and internal fixation devices ... Finland, Denmark, Sweden and Norway), Spain, Switzerland, the United Kingdom Market sizes, unit sales and ASPs are presented for the ...
November 2011
158 pages
US Denim Jeans Market Report: 2011 Edition
US$ 700.00
... Old Navy are the topmost women’s denim brands in the US. The report analyzes the denim jeans industry in the US. Market trends like introduction of new concepts ...
November 2011
34 pages
US Pharmacy Benefit Management (PBM) Industry Report: 2011 Edition
US$ 800.00
... chronic condition has also risen. The report analyzes the US Pharmacy Benefit Management Industry. Rising drug prices, increasing drug utilization and prevalence ... , contracts for renewals of the major players and market share of PBM companies adjusted on the basis of acquisitions and contract shifts. This ...
November 2011
40 pages
PHARMASSET - "IFN-free Oral Option" for HCV- Sharing the Big Pie!
US$ 140.00
Pharmasset (VRUS) may enjoy the first mover advantage in the race to offer the first “IFN free all oral option” to HCV pts. However the window ... read our report released on Nov. 16th, 2011 on VRUS titled “IFN-free Oral Option” for HCV- Sharing the Big Pie!
November 2011
9 pages
BIOGEN IDEC - Data of BG-12 + Sales Growth Brighten 2012 Prospects
US$ 140.00
Biogen Idec (BIIB) is closing 2011 with a positive note and ... Copaxone (L, RRMS) share of the MS market. Moreover, PhIIb data readouts from SELECT trial of Daclizumab HYP (PhII, IL-2 alpha subunit ... read our report, released on Nov. 8, 2011 on “Biogen Idec - Data of BG-12 + Sales Growth Brighten 2012 Prospects”
November 2011
6 pages
Mature Biotech: 3Q11 Earnings Summary
US$ 90.00
In this note we summarize the 3Q earnings of Mature Biotech – ALXN, AMGN, BIIB, CELG, GILD, and ONXX. We continue to reiterate ... PhIII data in mCRC). For more details, please read our 3Q11 earnings’ summary report released on 4th Nov, 2011 on “Mature Biotech: 3Q11 Earnings Summary”.
November 2011
5 pages
The U.S. Carpet Cleaning Industry
US$ 995.00
... (commercial, residential, disaster restoration), the market/competitors in carpet cleaning equipment, major trends and issues, factors affecting demand ( ... national, state, and city, by company size, truckmount operations, industry profitability trends, etc. Discussion of competition by large carpet mills, ...
October 2011
164 pages
PHARMASSET - 'IFN-Free Oral Option' for HCV - Not a Virgin Territory Anymore!
US$ 90.00
... ) wave to treat HCV the race to offer the first “IFN free all oral option” seems to have begun. Preliminary data from Abbott’s PhII trial ... ’11 is challenging Pharmasset (VRUS) multiprong approach. For more details, please read our report released on Oct. 24th, 2011 on VRUS titled “IFN-free Oral Option” for ...
October 2011
4 pages
Fats and Salad/Cooking Oils in the U.S.: Butter, Margarine, Olive Oil, and Beyond
US$ 3,500.00
... near $10.6 billion by 2016. Research supporting the important role of specific types of fat in maintaining health has caused many consumers to rethink the role ... and marketing. Major categories covered include butter, margarine, mayonnaise, cooking/salad oil, olive oil, cooking sprays, shortening, and popcorn ...
October 2011
175 pages
Latino Health and Beauty Care Shopper
US$ 3,500.00
... the market for HBC products in the United States. Over the past decade, spending by Latino consumers on personal care products grew more than 40%, ... consumers of HBC products in the future. Packaged Facts The Latino Health and Beauty Care Shopper provides an in-depth analysis of the grooming and personal ...
October 2011
146 pages
Private Label Credit Cards in the U.S., 7th Edition
US$ 3,750.00
... . With essentially all portfolios now being managed by third parties, improved credit quality and declining charge-offs, and indicators that consumer ... of key players’ individual receivables, retailers most important to the private label credit card market, and a discussion of top trends emerging in a digital ...
October 2011
196 pages
Tea and Ready-to-Drink Tea in the U.S., 4th Edition
US$ 3,850.00
... in the last year, with double digit gains from refrigerated tea. Ready-to-drink tea in general has been especially strong, particularly in natural food ... from Experian Simmons data, as well as a proprietary consumer survey on beverage and tea trends conducted by Packaged Facts. The report thoroughly maps out ...
October 2011
192 pages
US Medical Imaging Devices Market
US$ 1,000.00
The US has a dominant share in the global medical imaging devices industry. Commercialization of advanced systems, including multi-slice computer tomography (CT), high field magnetic resonance imaging...
October 2011
55 pages
